The EORTC and drug development
The EORTC and drug development
复制标题
EORTC 和药物开发
DOI：
10.1016/s0959-8049(01)00454-3
复制
发表时间：
2002
影响因子：
8.4
通讯作者：
J. Verweij
中科院分区：
文献类型：
--
作者：
D. Lacombe;P. Fumoleau;H. Zwierzina;C. Twelves;L. Hakansson;G. Jayson;F. Lehmann;J. Verweij
EORTC的早期药物开发一直受到结构变化的影响，以适应肿瘤药物开发的快速变化。早期药物开发人员的专业知识一直与疾病/肿瘤研究小组交叉受精，也回溯到实验室研究小组。这导致建立了一个坚实的、专门的医学肿瘤学家网络，专注于癌症药物开发的专业知识。EORTC数据中心配备了支持临床研究活动的所有专业知识，包括监管、安全和质量保证台。EORTC新药开发计划（NDDP）为早期临床试验提供方法学专业知识，并协调处理各种方法的I期和II期研究。通过NDDP，早期临床小组和以疾病/肿瘤为导向的小组已经建立了特定的网络，以解决特定肿瘤类型的早期药物开发。这就形成了一个非常高效的网络，拥有资源和患者，以标准化的方式处理和开展具有挑战性的临床试验，确保癌症治疗的最高标准。
Early drug development at EORTC has always been subject to structural changes to adapt to the rapid changes that occur in oncological drug development. The expertise of early drug developers has always been cross-fertilised with disease-/tumour-oriented groups and also backwards to the laboratory research groups. This results in the establishment of a solid and dedicated network of medical oncologists with focused expertise in cancer drug development. The EORTC Data Center is fully equipped with all expertise to support clinical research activities and includes regulatory, safety, and quality assurance desks. The EORTC New Drug development Programme (NDDP) provides methodological expertise to early clinical trials and coordinates phase I and phase II studies addressing various approaches. Through NDDP, the early clinical groups and the disease-/tumour-oriented groups have created specific networks to address early drug development in specific tumour types. This results in very efficient networks which have the resources and the patients to address and conduct challenging clinical trials in a standardised fashion ensuring the highest standards in cancer treatment.
晚期胰腺癌一线化疗后恶病质相关因素的恶化
DOI：
--
发表时间：
2016
期刊：
影响因子：
--
作者：
Mukohyama J;Iwakiri;D;Zen Y;Mukohara T;Minami H;Kakeji Y;Shimono Y.;Mitsunaga S.
通讯作者：
Mitsunaga S.